Genprex宣布澳大利亚知识产权局拟授予Reqorsa®基因疗法联合PD-L1抗体治疗癌症专利

美股速递02-10

Genprex公司今日披露，澳大利亚知识产权局已表达授予其专利的意向，该专利涵盖其研发的Reqorsa®基因疗法与PD-L1抗体联合使用的治疗方案，旨在攻克多种癌症。这一重要进展标志着公司在肿瘤治疗领域的创新技术获得国际权威认可，为后续临床开发与商业化奠定坚实基础。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1143451319?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-10 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143451319","market":"us","top_or_hot":-1,"title":"Genprex宣布澳大利亚知识产权局拟授予Reqorsa®基因疗法联合PD-L1抗体治疗癌症专利","media":"美股速递","content":"<p>Genprex公司今日披露，澳大利亚知识产权局已表达授予其专利的意向，该专利涵盖其研发的Reqorsa®基因疗法与PD-L1抗体联合使用的治疗方案，旨在攻克多种癌症。这一重要进展标志着公司在肿瘤治疗领域的创新技术获得国际权威认可，为后续临床开发与商业化奠定坚实基础。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genprex宣布澳大利亚知识产权局拟授予Reqorsa®基因疗法联合PD-L1抗体治疗癌症专利</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenprex宣布澳大利亚知识产权局拟授予Reqorsa®基因疗法联合PD-L1抗体治疗癌症专利\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-10 21:05 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Genprex公司今日披露，澳大利亚知识产权局已表达授予其专利的意向，该专利涵盖其研发的Reqorsa®基因疗法与PD-L1抗体联合使用的治疗方案，旨在攻克多种癌症。这一重要进展标志着公司在肿瘤治疗领域的创新技术获得国际权威认可，为后续临床开发与商业化奠定坚实基础。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1143451319","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143451319","pubTimestamp":1770728721,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Genprex公司今日披露，澳大利亚知识产权局已表达授予其专利的意向，该专利涵盖其研发的Reqorsa®基因疗法与PD-L1抗体联合使用的治疗方案，旨在攻克多种癌症。这一重要进展标志着公司在肿瘤治疗领域的创新技术获得国际权威认可，为后续临床开发与商业化奠定坚实基础。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","GNPX":"Genprex, Inc."},"translate_title":"Genprex Announces Intellectual Property Australia Proposed Award to Reqorsa ® Gene therapy combined with PD-L1 antibody to treat cancer patent","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GNPX":1},"content_text":"Genprex公司今日披露，澳大利亚知识产权局已表达授予其专利的意向，该专利涵盖其研发的Reqorsa®基因疗法与PD-L1抗体联合使用的治疗方案，旨在攻克多种癌症。这一重要进展标志着公司在肿瘤治疗领域的创新技术获得国际权威认可，为后续临床开发与商业化奠定坚实基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143451319","isCrawlerRequest":true}